AOD-9604: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข4 community protocols documented
- โขEvidence level: Structured Community Data
- โขBased on 90 community reports
- โข3 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Clinical Trial Results | Six human clinical trials involving over 900 participants were conducted. The largest Phase IIb trial failed to achieve statistical significance for weight loss. A smaller 12-week study showed modest fat loss (2.8 kg vs 0.8 kg placebo) at 1 mg daily. Development was terminated in 2007. | Community interest persists despite the failed Phase IIb trial. Users cite the smaller positive trial and the GRAS safety designation. Self-reported outcomes suggest modest fat loss when combined with diet and exercise. | high The disconnect between a failed pivotal clinical trial and continued community interest is significant. Community expectations should be calibrated against the clinical data showing modest effects at best. |
| Administration Route | Clinical trials tested both oral and injectable (subcutaneous) AOD-9604. The oral route was investigated in early trials. | Community primarily uses subcutaneous injection. An oral formulation has gained recent interest, partly driven by AOD-9604 receiving GRAS (Generally Recognized As Safe) status for use as a food ingredient in the US. | moderate AOD-9604 is one of the few research peptides with both injectable and oral community use patterns. The GRAS designation applies to oral use as a food supplement, not therapeutic use. |
| GRAS Status Interpretation | AOD-9604 received GRAS status from the FDA for use as a food ingredient, meaning it is considered safe for consumption in food products at specified levels. This is not a therapeutic approval. | Some community members interpret GRAS status as implicit FDA approval for therapeutic fat loss use, which is incorrect. GRAS applies only to safety as a food ingredient, not efficacy for any medical condition. | high The distinction between GRAS food safety status and therapeutic approval is frequently misunderstood in the community. |
Compare these community approaches with published research findings.
Community Protocols
Standard Fat Loss Protocol
Popular- Route
- Subcutaneous
- Dose
- 300 mcg
- Frequency
- Once daily (AM fasted)
- Duration
- 12-16 weeks
Most commonly reported protocol; injected on empty stomach in the morning. Based on clinical trial dose.
Split Dose Protocol
Common- Route
- Subcutaneous
- Dose
- 250 mcg per injection
- Frequency
- Twice daily (AM fasted + pre-bed)
- Duration
- 12-16 weeks
Total 500 mcg daily split between morning and evening; both injections on empty stomach
High-Dose Protocol
Common- Route
- Subcutaneous
- Dose
- 500 mcg
- Frequency
- Once daily
- Duration
- 8-12 weeks
Higher dose used by some clinics; based on the upper range of clinical trial data
Oral AOD-9604 Protocol
Niche- Route
- Oral
- Dose
- 300-600 mcg
- Frequency
- Once daily
- Duration
- 12+ weeks
Oral formulation gaining popularity; AOD-9604 was originally studied via oral route in some trials. GRAS status in the US as a food supplement.
Stacking Patterns
AOD-9604 + CJC-1295/Ipamorelin
CommonFat-specific lipolysis from AOD-9604 combined with GH secretagogue effects for comprehensive body composition improvement
AOD-9604 + Tesamorelin
NicheDual fat-reduction approach; AOD-9604 for peripheral fat metabolism and tesamorelin for GHRH-mediated visceral fat reduction
AOD-9604 + HGH Fragment 176-191
NicheRelated peptide comparison; AOD-9604 is a modified version of Fragment 176-191. Some users try both to compare subjective effects.
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 90+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|AOD-9604 experience reports and fat loss discussions(accessed 2026-02-16)
- Reddit r/PeptideResearch|AOD-9604 protocol and GRAS status discussions(accessed 2026-02-16)
- Alpha Rejuvenation|AOD-9604 Dosage Complete Clinical Protocol for Fat Loss(accessed 2026-02-16)
- Revolution Health|AOD-9604 Peptide for Fat Loss and Metabolic Support(accessed 2026-02-16)
- Swolverine|AOD-9604 Dosage Guide (protocols, benefits, side effects, stacking)(accessed 2026-02-16)
- Yahoo Finance (Expert Analysis)|AOD-9604 Peptide Expert Analysis Reviews Benefits and Side Effects (2026)(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for AOD-9604 (Anti-Obesity Drug 9604). The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
AOD-9604 occupies an unusual position in the peptide community as a peptide with extensive clinical trial history (six human trials, 900+ participants), GRAS food safety status, and yet a failed pivotal efficacy trial. Despite the mixed clinical record, community interest remains strong, driven partly by the favorable safety profile and partly by anecdotal fat loss reports.
Understanding Protocol Divergence#
Failed Clinical Trial Context#
The most important context for AOD-9604 community use is that the largest clinical trial (Phase IIb) did not demonstrate statistically significant weight loss. This is frequently downplayed in community discussions and vendor marketing. A smaller trial showed modest results, but the peptide's development was terminated in 2007 by Metabolic Pharmaceuticals.
GRAS Status Misinterpretation#
AOD-9604's GRAS (Generally Recognized As Safe) status for use as a food ingredient is frequently misunderstood as implicit FDA approval for therapeutic use. GRAS applies only to safety as a food additive at specified levels and does not validate any health claims or therapeutic efficacy.
Commonly Reported Outcomes#
Community members frequently report the following when using AOD-9604:
- Modest fat loss: Gradual reduction in body fat, typically noticed at 8-12 weeks, often described as subtle
- No appetite effects: Unlike GH secretagogues, AOD-9604 does not typically affect appetite
- No blood sugar impact: Users report stable blood glucose, consistent with clinical data
- Minimal side effects: Generally well-tolerated with few reported side effects
- Underwhelming for some: A significant portion of users report minimal noticeable effects
Important Caveats#
- The pivotal clinical trial failed to show significant weight loss
- GRAS status does not equal therapeutic approval
- Self-reported fat loss is difficult to separate from diet and exercise changes
- Community expectations may be inflated relative to clinical evidence
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About AOD-9604
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.